Semax 10mg+Selank 10mg

Compound Overview

Research Use Only. Not for Human Consumption.

Semax 10mg+Selank 10mg is a Nexus-only multi-peptide research blend supplied as a 20mg lyophilized powder configuration. The blend contains two listed components: Semax at 10mg and Selank at 10mg. Within the source record, Semax is identified as an ACTH-fragment analog component, while Selank is identified as a tuftsin analog component.

This product is assigned to the Cognitive & Nootropic category and is listed under SKU XS20. The source data describes the material as a blend rather than a single compound, so there is no single molecular formula, molecular weight, sequence, or CAS number that applies to the complete product. Component-level chemistry should be reviewed through the individual parent compound records rather than inferred at the blend level.

Because the current product record for this exact blend is intentionally limited, this page does not add unsupported chemistry, analytical values, literature claims, dosage language, or human-use guidance. All information below is restricted to the product and research data supplied for this Nexus catalog item.

Research Background & Published Literature

The available research file identifies XS20 as a Nexus-only Semax/Selank research blend. It does not provide blend-specific citations, experimental abstracts, mechanism summaries, or published literature entries for this exact 10mg+10mg configuration. For that reason, no peer-reviewed citations are listed here and no component-level research claims are repeated without direct source support.

The source record does specify that a Certificate of Analysis should verify both component identities and mass allocation for this blend. That distinction matters for multi-peptide materials: the analytical review should address the presence of each named component rather than treating the item as a single molecule with one formula, one molecular weight, or one sequence.

Researchers evaluating this product should treat it as a blend record. Any study design, analytical method, or comparison workflow should separately account for the Semax component and the Selank component using validated laboratory procedures and the applicable parent-compound references available to the research team.

Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:

• Gusev et al. (2018) — Zh Nevrol Psikhiatr Im S S Korsakova
• Liu et al. (2025) — Br J Pharmacol
• Vyunova et al. (2018) — Protein Pept Lett
• Panikratova et al. (2020) — Dokl Biol Sci

Storage, Handling & Stability Guidelines

Store lyophilized Semax 10mg+Selank 10mg material at -20°C, desiccated, and protected from light. These conditions are the only storage parameters provided in the source record for this exact blend.

After reconstitution, aliquot the material and avoid repeated freeze-thaw cycles. The source record does not specify a reconstituted shelf life, diluent, working concentration, or post-reconstitution storage duration, so those details should be controlled by validated laboratory SOPs rather than inferred from this page.

• Maintain protection from moisture and light during storage and handling.
• Use aliquoting practices to reduce repeated freeze-thaw exposure after reconstitution.
• Do not assign a blend-level molecular weight, formula, CAS number, or sequence unless confirmed by a validated source.
• Retain internal handling records that identify the product name, SKU, total blend amount, and date of reconstitution when applicable.

Lab Verification

Nexus maintains a Lab Verified workflow for research materials. For this exact blend, the current product record does not include batch-specific COA attributes, normalized purity values, retention data, mass-found values, batch identifiers, or test dates. No exact COA values are therefore stated on this page.

For a multi-peptide blend such as Semax 10mg+Selank 10mg, lab verification should address both component identities and mass allocation. In general terms, HPLC/MS verification can support chromatographic review and mass-spectrometry identity confirmation, but any exact result must come from the applicable batch COA rather than from a generated product description.